David B Solit MD

PubMed

• 7 citations
  Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.
  Carissa E Chu, Ziyu Chen, Karissa Whiting, Irina Ostrovnaya, Andrew T Lenis
  European Urology. 2025-11-01
• Comprehensive Molecular, Pathological, and Clinical Characterization of Clear Cell Adenocarcinoma of the Urinary Tract.
  Rayan Rammal, Florestan J Koll, Ziyu Chen, Jacob E Tallman, Syed Muneeb Alam
  Modern Pathology. 2025-10-01
• Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.
  Bob T Li, Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières
  Clinical Lung Cancer. 2025-10-01

Journal Articles

• Article Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer  
  Sarat Chandarlapaty, Alison M Schram, David M Hyman, David B Solit, ScienceDirect
• Neratinib Is Effective in Breast Tumors Bearing Both Amplification and Mutation of ERBB2 (HER2)  
  José Baselga, Kyriakos P. Papadopoulos, Sarat Chandarlapaty, David B. Solit, Science Magazine
• Genome Doubling Shapes the Evolution and Prognosis of Advanced Cancers  
  Alison M Schram, Mark E Robson, David B Solit, Zsofia K Stadler, Nature

Abstracts/Posters

• Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase
  David B. Solit, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Drugging the Undruggable 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Role of cfDNA in the Treatment of Patients With Advanced Cancer 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018